Wockhardt Ltd

Wockhardt Ltd

₹ 1,779 -2.91%
12 Jun 3:01 p.m.
About

Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]

Key Points

Market Position
The company is amongst the top 3 Indian generic companies in the UK and the 6th largest generic supplier in the retail and hospital channels in Ireland. It is the No. 1 Methycobalamin brand in India. [1]

  • Market Cap 28,912 Cr.
  • Current Price 1,779
  • High / Low 1,862 / 552
  • Stock P/E
  • Book Value 268
  • Dividend Yield 0.00 %
  • ROCE 3.75 %
  • ROE -1.22 %
  • Face Value 5.00

Pros

Cons

  • Stock is trading at 6.76 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 1.15% over past five years.
  • Company has a low return on equity of -6.95% over last 3 years.
  • Promoter holding has decreased over last 3 years: -18.0%
  • Working capital days have increased from 67.0 days to 127 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
655 595 679 699 678 644 753 701 700 739 809 721 743
688 611 636 654 675 628 681 664 759 648 699 593 679
Operating Profit -33 -16 43 45 3 16 72 37 -59 91 110 128 64
OPM % -5% -3% 6% 6% 0% 2% 10% 5% -8% 12% 14% 18% 9%
-169 57 -138 -1 -64 0 24 8 10 30 9 8 15
Interest 86 73 70 83 76 79 76 77 73 73 73 60 48
Depreciation 59 64 65 66 56 55 55 55 58 54 55 55 53
Profit before tax -347 -96 -230 -105 -193 -118 -35 -87 -180 -6 -9 21 -22
Tax % -10% -22% -10% -3% 23% 15% 109% -1% -2% 167% 78% 5% 105%
-311 -75 -207 -102 -237 -136 -73 -86 -177 -16 -16 20 -45
EPS in Rs -17.91 -4.65 -13.12 -6.66 -14.44 -9.30 -5.34 -5.76 -11.02 -0.91 -1.43 0.86 -1.54
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
4,830 4,482 4,453 4,015 3,937 3,566 2,844 2,708 3,230 2,651 2,798 3,012
3,805 3,772 3,959 4,002 3,935 3,604 2,725 2,771 2,932 2,549 2,707 2,619
Operating Profit 1,026 709 494 13 2 -38 119 -63 298 102 91 393
OPM % 21% 16% 11% 0% 0% -1% 4% -2% 9% 4% 3% 13%
88 67 66 114 -238 116 133 975 -163 -173 17 62
Interest 83 55 129 225 255 265 276 249 299 302 305 254
Depreciation 140 145 142 149 150 164 224 246 247 251 223 217
Profit before tax 891 575 289 -247 -641 -351 -247 417 -411 -624 -420 -16
Tax % 5% 28% 13% -9% 4% -38% -82% -65% -32% -0% 12% 256%
843 413 252 -226 -667 -217 -43 688 -279 -621 -472 -57
EPS in Rs 58.91 28.30 17.45 -13.62 -42.30 -13.52 -4.81 47.64 -16.94 -38.80 -30.18 -2.89
Dividend Payout % 13% 54% 0% -56% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -4%
5 Years: 1%
3 Years: -2%
TTM: 8%
Compounded Profit Growth
10 Years: %
5 Years: -2%
3 Years: 15%
TTM: 88%
Stock Price CAGR
10 Years: 4%
5 Years: 51%
3 Years: 98%
1 Year: 209%
Return on Equity
10 Years: -2%
5 Years: 0%
3 Years: -7%
Last Year: -1%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 55 55 55 55 55 55 55 55 72 72 77 81
Reserves 3,228 3,362 3,720 3,281 2,797 2,619 2,616 3,321 3,777 3,282 3,282 4,272
2,205 2,309 2,677 4,160 3,748 3,375 3,582 2,674 2,198 2,184 2,356 2,021
1,134 1,213 1,622 1,486 1,528 1,764 1,894 1,696 2,168 2,113 1,899 1,761
Total Liabilities 6,622 6,939 8,074 8,982 8,128 7,813 8,148 7,746 8,215 7,651 7,614 8,135
2,295 2,123 2,809 2,773 2,888 3,058 3,502 3,343 3,462 3,042 2,881 4,256
CWIP 708 1,007 1,036 1,244 1,433 1,445 1,585 1,379 1,342 1,539 1,722 513
Investments 577 341 0 563 214 0 0 0 0 0 0 422
3,043 3,468 4,228 4,403 3,593 3,309 3,060 3,024 3,411 3,070 3,011 2,944
Total Assets 6,622 6,939 8,074 8,982 8,128 7,813 8,148 7,746 8,215 7,651 7,614 8,135

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1,476 355 -42 -269 68 183 649 -287 413 153 219 -22
-823 -222 -105 -684 635 93 -147 1,471 -204 -118 -138 -783
-601 -76 193 1,254 -769 -776 -680 -1,171 -71 -315 334 409
Net Cash Flow 52 57 46 301 -66 -500 -178 13 138 -280 415 -396

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 36 60 91 94 89 130 159 124 104 110 81 80
Inventory Days 201 250 249 243 174 183 209 256 222 216 201 234
Days Payable 113 136 144 117 122 187 272 223 265 285 240 191
Cash Conversion Cycle 124 175 196 220 141 126 97 157 60 41 41 123
Working Capital Days 9 43 97 96 -16 7 -47 122 62 53 21 127
ROCE % 18% 10% 7% -1% -1% -1% 0% 12% 1% -0% -1% 4%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
65.75% 63.83% 60.36% 59.31% 58.40% 55.14% 54.93% 51.60% 51.99% 51.99% 49.09% 49.09%
2.82% 2.98% 2.87% 2.78% 2.60% 3.03% 4.18% 5.49% 5.94% 6.70% 6.54% 6.82%
0.09% 0.15% 0.22% 0.22% 0.18% 0.21% 0.30% 4.82% 4.45% 5.08% 9.82% 10.58%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.02% 0.02% 0.02%
31.34% 33.04% 36.55% 37.70% 38.83% 41.62% 40.59% 38.06% 37.62% 36.21% 34.54% 33.50%
No. of Shareholders 1,80,1701,80,6331,84,9081,82,4931,78,9151,72,9891,61,8131,46,1381,40,3911,38,1421,42,7101,41,799

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls